Comparative Study to Evaluate ISV-305 Compared to Vehicle in Blepharitis Subjects

Summary

The purpose of this study is to evaluate the clinical efficacy and safety of ISV-305 (Dexamethasone in DuraSite® 2) compared to Vehicle in the treatment of subjects with active, symptomatic Blepharitis.

Timeline

Start

2018-03-30

Primary completion

2020-02-04

Completion

2020-02-04

Outcome

Met primary endpoint

registry analysis (superiority test); ISV-305 vs Vehicle; p = 0.0354; Risk Difference (RD) 8.5 (95% CI 0.2 to 16.6); Fisher Exact; NCT01543490 ↗

Drugs

Indications